Detail akcie Tonix Pharm Hld Rg online

Business Summary: Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tonix Pharmaceuticals Holding Corp revenues increased 3% to $7.7M. Net loss decreased 29% to $77.1M. Revenues reflect Information and Concentrations segment increase of 53% to $7.7M. Lower net loss reflects Information and Concentrations segment loss decrease of 17% to $77.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$2542.31 to -$10.29.